Skip to content

Matthew Baggott

2 papers in the library · 44 citations · publishing 2024-2025

Papers

Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement.

JAMA network open June 3, 2024 Amy L McGuire, I Glenn Cohen, Dominic Sisti et al. 41 citations

A consensus statement from a 2023 meeting of 27 experts identifies 20 points of consensus across five ethical issues for integrating psychedelic medicines into mainstream medical practice: reparations and reciprocity, equity, and respect; informed consent; professional boundaries and physical touch; personal experience; and gatekeeping. The meeting included clinicians, researchers, Indigenous groups, industry, philanthropy, veterans, retreat facilitators, training programs, and bioethicists. The statement focuses on government-approved medical use in the US and abroad, emphasizing that policymakers must address challenges ahead while acknowledging the hopeful moment.

Psychedelic Assisted Therapy as a Complex Intervention: Implications for clinical trial design

PsyArXiv February 23, 2025 Suresh Muthukumaraswamy, Matthew Baggott, Eduardo Ekman Schenberg et al. 3 citations preprint

Psychedelic-assisted therapy (PAT) is a complex, multi-component intervention, yet most clinical trials evaluate it as a simple pharmaceutical treatment, limiting real-world validity. This position piece advocates applying the UK Medical Research Council's complex intervention framework to PAT, emphasizing theory of change, structured development, context, and stakeholder input. Pragmatic randomized controlled trials, informed by the PRECIS-2 tool, are proposed to align trial designs with real-world healthcare settings. The authors contrast drug-centric and psychotherapy-augmented views of PAT's efficacy, and recommend integrating qualitative data, adaptive designs, and comparative effectiveness research. A pluralistic evidentiary model is suggested to advance psychedelic medicine while avoiding past developmental pitfalls.